Coherus Oncology Inc. reported its financial results for the second quarter of 2025, noting a significant increase in LOQTORZI net revenue, which rose to $10.0 million-a 36% increase over the first quarter of 2025. The company recorded a non-GAAP net loss from continuing operations of $39.0 million for the second quarter, an increase from the $34.7 million loss reported for the same period in 2024. For the first half of 2025, the non-GAAP net loss was $79.9 million, an improvement compared to the $88.3 million loss in the first half of 2024. Selling, general, and administrative expenses decreased to $26.0 million from $27.5 million in the same period of the previous year, attributed mainly to lower headcount and decreased operating costs following recent divestitures. The company ended the second quarter with $238 million in cash, cash equivalents, and marketable securities, asserting a cash runway through 2026. Coherus remains focused on maximizing LOQTORZI's potential in treating nasopharyngeal carcinoma and anticipates data readouts for CHS-114 and casdozokitug in the first half of 2026.